Mark N. Polizzotto

4.3k total citations
100 papers, 2.5k citations indexed

About

Mark N. Polizzotto is a scholar working on Oncology, Epidemiology and Pathology and Forensic Medicine. According to data from OpenAlex, Mark N. Polizzotto has authored 100 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 30 papers in Epidemiology and 23 papers in Pathology and Forensic Medicine. Recurrent topics in Mark N. Polizzotto's work include Viral-associated cancers and disorders (42 papers), Lymphoma Diagnosis and Treatment (23 papers) and Cytomegalovirus and herpesvirus research (14 papers). Mark N. Polizzotto is often cited by papers focused on Viral-associated cancers and disorders (42 papers), Lymphoma Diagnosis and Treatment (23 papers) and Cytomegalovirus and herpesvirus research (14 papers). Mark N. Polizzotto collaborates with scholars based in Australia, United States and United Kingdom. Mark N. Polizzotto's co-authors include Thomas S. Uldrick, Robert Yarchoan, Denise Whitby, Vickie Marshall, Kathleen M. Wyvill, Karen Aleman, Seth M. Steinberg, Richard F. Little, Stefania Pittaluga and Perry F. Bartlett and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mark N. Polizzotto

93 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark N. Polizzotto Australia	26	1.4k	655	616	440	364	100	2.5k
Mónica Marazuela Spain	38	933 0.7×	322 0.5×	922 1.5×	322 0.7×	383 1.1×	202	5.2k
Pierre Lévy France	32	985 0.7×	192 0.3×	440 0.7×	248 0.6×	87 0.2×	115	3.2k
Chul Kim United States	27	1.1k 0.8×	181 0.3×	353 0.6×	127 0.3×	88 0.2×	135	2.4k
John L. Frater United States	21	355 0.3×	378 0.6×	193 0.3×	153 0.3×	347 1.0×	86	1.5k
Paul Martin United States	27	429 0.3×	224 0.3×	810 1.3×	407 0.9×	436 1.2×	109	3.1k
Florian Weißinger Germany	24	952 0.7×	472 0.7×	321 0.5×	47 0.1×	130 0.4×	73	2.6k
Atsushi Satō Japan	26	665 0.5×	298 0.5×	194 0.3×	142 0.3×	59 0.2×	190	2.6k
Cheryl Hemingway United Kingdom	31	234 0.2×	1.5k 2.3×	548 0.9×	272 0.6×	686 1.9×	91	3.8k
Torsten Witte Germany	31	227 0.2×	464 0.7×	253 0.4×	559 1.3×	176 0.5×	195	3.3k
Carmen Martı́nez Spain	34	881 0.6×	526 0.8×	368 0.6×	144 0.3×	139 0.4×	146	3.1k

Countries citing papers authored by Mark N. Polizzotto

Since Specialization

Citations

This map shows the geographic impact of Mark N. Polizzotto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Polizzotto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Polizzotto more than expected).

Fields of papers citing papers by Mark N. Polizzotto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark N. Polizzotto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Polizzotto. The network helps show where Mark N. Polizzotto may publish in the future.

Co-authorship network of co-authors of Mark N. Polizzotto

This figure shows the co-authorship network connecting the top 25 collaborators of Mark N. Polizzotto. A scholar is included among the top collaborators of Mark N. Polizzotto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark N. Polizzotto. Mark N. Polizzotto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramaswami, Ramya, Kathryn Lurain, Mark N. Polizzotto, et al.. (2025). Characteristics and outcomes of Kaposi sarcoma herpesvirus–associated inflammatory cytokine syndrome. Blood Advances. 9(22). 5720–5731. 1 indexed citations

Marshall, Vickie, Charles Goodman, A. Jayakumaran Nair, et al.. (2024). Sequencing of Kaposi’s Sarcoma Herpesvirus (KSHV) genomes from persons of diverse ethnicities and provenances with KSHV-associated diseases demonstrate multiple infections, novel polymorphisms, and low intra-host variance. PLoS Pathogens. 20(7). e1012338–e1012338. 4 indexed citations

Khan, Shanchita R., Eva Stadler, Timothy E. Schlub, et al.. (2024). Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis. The Lancet Microbe. 5(5). e459–e467. 9 indexed citations

Bennedbæk, Marc, Miglė Gabrielaitė, Preston Leung, et al.. (2023). Associations of functional human leucocyte antigen class I groups with HIV viral load in a heterogeneous cohort. AIDS. 37(11). 1643–1650. 1 indexed citations

Khan, Shanchita R., Eva Stadler, Timothy E. Schlub, et al.. (2023). Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis. medRxiv. 1 indexed citations

García, Féderico, Anders Sönnerborg, Michael Böhm, et al.. (2023). Generating synthetic clinical data that capture class imbalanced distributions with generative adversarial networks: Example using antiretroviral therapy for HIV. Journal of Biomedical Informatics. 144. 104436–104436. 20 indexed citations

Safo, Sandra E., Jason V. Baker, Cavan Reilly, et al.. (2023). Derivation of a Protein Risk Score for Cardiovascular Disease Among a Multiracial and Multiethnic HIV+ Cohort. Journal of the American Heart Association. 12(13). e027273–e027273. 2 indexed citations

Polizzotto, Mark N., Sam Milliken, Tara Cochrane, et al.. (2023). Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. British Journal of Haematology. 201(5). 865–873. 4 indexed citations

Stadler, Eva, Timothy E. Schlub, Shanchita R. Khan, et al.. (2023). Monoclonal antibody levels and protection from COVID-19. Nature Communications. 14(1). 4545–4545. 26 indexed citations

10.

Carbone, Antonino, Margaret Borok, Blossom Damania, et al.. (2021). Castleman disease. Nature Reviews Disease Primers. 7(1). 96 indexed citations

11.

Ramaswami, Ramya, Thomas S. Uldrick, Mark N. Polizzotto, et al.. (2019). A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. Clinical Cancer Research. 25(14). 4238–4247. 23 indexed citations

12.

Lurain, Kathryn, Mark N. Polizzotto, Karen Aleman, et al.. (2019). Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 133(16). 1753–1761. 83 indexed citations

13.

Dharan, Nila J., Kathy Petoumenos, Prabhjot Juneja, et al.. (2019). Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in Australia. AIDS Research and Human Retroviruses. 36(4). 291–296. 3 indexed citations

14.

Polizzotto, Mark N., Thomas S. Uldrick, Kathleen M. Wyvill, et al.. (2016). Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. Journal of Clinical Oncology. 34(34). 4125–4131. 86 indexed citations

15.

Polizzotto, Mark N., Thomas S. Uldrick, Kathleen M. Wyvill, et al.. (2015). Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clinical Infectious Diseases. 62(6). 730–738. 141 indexed citations

16.

Uldrick, Thomas S., Mark N. Polizzotto, Karen Aleman, et al.. (2014). Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 124(24). 3544–3552. 80 indexed citations

17.

McQuilten, Zoe, Erica M. Wood, Mark N. Polizzotto, et al.. (2014). Underestimation of Myelodysplastic Syndrome Incidence by Cancer Registries. Cancer. 120(11). 1 indexed citations

18.

Gasperini, Paola, Georgina Espígol‐Frigolé, Peter J. McCormick, et al.. (2012). Kaposi Sarcoma Herpesvirus Promotes Endothelial-to-Mesenchymal Transition through Notch-Dependent Signaling. Cancer Research. 72(5). 1157–1169. 89 indexed citations

19.

Ray, Alex, Vickie Marshall, Thomas S. Uldrick, et al.. (2012). Sequence Analysis of Kaposi Sarcoma–Associated Herpesvirus (KSHV) MicroRNAs in Patients with Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome. The Journal of Infectious Diseases. 205(11). 1665–1676. 31 indexed citations

20.

Polizzotto, Mark N. & Greg Whelan. (2007). Hepatitis B immunity in a population of drug and alcohol users. Drug and Alcohol Review. 26(4). 417–419. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact